Study S000330

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00393718
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 400
Start: 2006-11
Primary completion: 2007-11
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:glibenclamide; DRUG:placebo
Results posted: TRUE

Registered primary outcomes

Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment [after 24 weeks of treatment]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020069	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Alves C, Diabetes research and clinical practice	2012	Systematic review	PMID 23010561 DOI	registry reference RESULT:23010561
R0022306	The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes. Seino Y, Journal of diabetes investigation	2012	Randomized trial	PMID 24843595 DOI	cites ClinicalTrials.gov:NCT00393718; registry reference RESULT:24843595
R0020188	GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. Hegedüs L, The Journal of clinical endocrinology and metabolism	2011	Preclinical	PMID 21209033 DOI	cites ClinicalTrials.gov:NCT00393718; registry reference DERIVED:21209033
R0022766	Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. Kaku K, Journal of diabetes investigation	2011	Randomized trial	PMID 24843528 DOI	cites ClinicalTrials.gov:NCT00393718
R0024648	Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Seino Y, Current medical research and opinion	2010	Randomized trial	PMID 20199137 DOI	cites ClinicalTrials.gov:NCT00393718; registry reference RESULT:20199137